Arvinas : Corporate Presentation – January 2022

Pioneering the future of targeted protein degradation therapeutics

January 2022

Safe harbor and forward-looking statements

This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including statements regarding the receipt of upfront, milestone and other payments under the Pfizer collaboration, the potential benefits of our arrangements with our collaborative partnerships, the development and regulatory status of our product candidates, such as statements with respect to our lead product candidates, ARV-110,ARV-471 and ARV-766 and other candidates in our pipeline, and the timing of clinical trials and data from those trials and plans for registration for our product candidates, and our discovery programs that may lead to our development of additional product candidates, the potential utility of our technology and therapeutic potential of our product candidates, the potential commercialization of any of our product candidates, and the sufficiency of our cash resources. All statements, other than statements of historical facts, contained in this presentation, including statements regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words "anticipate," "believe," "estimate," "expect," "intend," "may," "might," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make as a result of various risks and uncertainties, including but not limited to: each party's performance of its obligations under the Pfizer collaboration, whether we and Pfizer will be able to successfully conduct and complete clinical development for ARV-471, whether we will be able to successfully conduct and complete clinical development for ARV-110 and ARV-766, initiate and complete other clinical trials for our product candidates, and receive results from our clinical trials on our expected timelines, or at all, whether our cash resources will be sufficient to fund our foreseeable and unforeseeable operating expenses and capital expenditure requirements and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, discussed in the "Risk Factors" section of the Company's quarterly and annual reports on file with the Securities and Exchange Commission. The forward-looking statements contained in this presentation reflect our current views as of the date of this presentation with respect to future events, and we assume no obligation to update any forward-looking statements except as required by applicable law.

The Arvinas name and logo are our trademarks. We also own the service mark and the registered U.S. trademark for PROTAC®. The trademarks, trade names and service marks appearing in this presentation are the property of their respective owners. We have omitted the ® and ™ designations, as applicable, for the trademarks named in this presentation.

This presentation also contains estimates and other statistical data made by independent parties and by us relating to market size and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such data and estimates. In addition, projections, assumptions and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk.

2

Arvinas: Advancing a new therapeutic modality to patients

PROTEIN DEGRADATION

• PROTAC® (proteolysis-targeting chimeras) protein degraders eliminate vs. inhibit disease-causing proteins
• Combines the power of genetic knockdown technology with the benefits of small- molecule therapeutics

PIPELINE

2 Programs in Phase 2

Clear efficacy signals in patients with difficult-to-treat breast and prostate cancers

1 Program in Phase 1

20+ Pipeline Programs

ARV-471ARV-110

ARV-766

ARVINAS 290+team

members

• Founded in 2013 by the original PROTAC pioneer
• Protein degradation platform with clinical proof of concept

in oncology, I-O, and neuroscience

PARTNERED FOR

SUCCESS

Global collaboration with Pfizer to co-develop and co-commercializeARV-471 in ER+ breast cancer announced in July 2021

3

A history of pioneering since our founding

	JULY 2001		2019	2020	JULY 2021
	Arvinas' founder	LATE 2016	ARV-110 Phase 2	Partnered with Pfizer
	PROTAC clinical
Craig Crews publishes	Arvinas creates	initiated	to co-develop and
studies:
first paper describing		co-commercialize
first oral PROTAC	ARV-110 and ARV-471
PROTAC® degraders		ARV-471

JULY 2013	EARLY 2018	2020	2021
Arvinas founded to turn	Arvinas creates first	Efficacy proof of concept	ARV-471 Phase
protein degraders into	BBB-crossing PROTAC	for ARV-110 and ARV-471	2 initiated
patient therapies	degraders

BBB, blood-brain barrier	4

PROTAC® protein degraders harness the ubiquitin-proteasome system to induce the degradation of disease-causing proteins

1 Complex Formation

Recognizing disease- causing protein

PROTAC

E3 ligase

Target

Protein

PROTAC

2 Protein Tagging	3 Protein Elimination
Tagging of target	Target protein is degraded by
protein for degradation	the proteasome

Ubiquitin

Proteasome

Iterative
activity	5